Markets
Physician Views Results: Merck & Co.’s tulisokibart could have a moderate-to-major impact on HS treatment landscape, say most dermatologists – FirstWord Pharma
Physician Views Results: Merck & Co.'s tulisokibart could have a moderate-to-major impact on HS treatment landscape, say most…